14/08/2026
Latigo Biotherapeutics
Goes Public
$18.00 per share
Latigo Biotherapeutics priced its IPO at $18 per share, offering 19.2 million shares on Nasdaq under the ticker LTGO. The clinical-stage biotech aims to fund non-opioid pain management treatments.
SwissCore 🇨🇭